English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Ovarian cancer is the most common malignant cancer among females. This study aimed to investigate role of the CXCL12-CXCR4/CXCR7 chemokine axis in ovarian cancer. Material and methods: SKOV3 cells were transfected with siCXCR4/siCXCR7 plasmids and divided into SKOV3, LV3, LV3-siCXCR4, and LV3-siCXCR7 groups. Cell viability and apoptosis were examined using MTT and flow cytometry. ELISA was conducted to evaluate vascular-endothelial growth factor-A (VEGF-A), interleukin-6 (IL-6), and interleukin-8 (IL-8) levels. SKOV3 cells were transplanted into mice to establish a  Xenograft model. The tumour volume of the Xenograft model was recorded. CD31, matrix-metalloprotein-9 (MMP-9), vimentin, and E-cadherin expressions in SKOV3 cells and tumour tissues were evaluated with quantitative real-time PCR (qRT-PCR) and western blot. Immunohistochemistry assay was used to detect VEGF-A, CD31, MMP-9, vimentin, and E-cadherin expression. Results: SKOV3 cells strongly expressed CXCR4 and CXCR7. CXCL12 significantly enhanced cell viability, and CXCR4/CXCR7 inhibitor remarkably reduced cell viability of SKOV3 (p < 0.05). CXCR4/CXCR7 gene-silencing significantly decreased SKOV3 viability compared to the SKOV3 or LV3 group (p < 0.05). CXCR4/CXCR7 gene-silencing modulated cell cycle and increased apoptosis rates compared to SKOV3 or LV3 group (p < 0.05). CXCR4/CXCR7 gene-silencing inhibited VEGF-1, IL-6, and IL-8 secretion. CXCR4/CXCR7 gene-silencing modulated levels of CD31, MMP-9, vimentin, and E-cadherin. CXCR4/CXCR7 gene-silencing suppressed p-ERK1/2 (p  < 0.05) and strengthened inhibitive effects of CXCR4/CXCR7 inhibitor on p-ERK1/2. CXCR4/CXCR7 gene-silencing reduced tumour volume and regulated tumourigenesis-associated molecules in the mouse Xenograft model. Conclusions: CXCR4/CXCR7 gene-silencing could suppress ovarian cancer cell proliferation and tumour growth through modulation of the CXCL12CXCR4/CXCR7 chemokine axis and mitogen-activated protein kinase (MAPK) signalling pathway.

archives of medical science/archives of medical science (online)

CXCR4/CXCR7 gene-silencing suppresses ovarian cancer cell proliferation and tumour growth through modulation of the CXCL12-CXCR4/CXCR7 chemokine axis and activation of MAPK signalling pathway